Search Result

Results for "

diabetic complications

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Aldose Reductase (13) Apoptosis (2) Autophagy (2) Dipeptidyl Peptidase (2) GCGR (1) Glucosidase (1) GLUT (1) Histone Methyltransferase (1) Insulin Receptor (1) NF-κB (1) p38 MAPK (1) Thrombin (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (2) Endocrinology (3) Inflammation/Immunology (3) Metabolic Disease (17) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150630

ALR2-IN-1	Aldose Reductase	Metabolic Disease
ALR2-IN-1 is a potent and selective ALR2 inhibitor (IC₅₀=1.42 μM). ALR2-IN-1 shows antioxidant and antiglycative properties. ALR2-IN-1 can be used in diabetic complication research .

HY-17374

Benfotiamine 1 Publications Verification S-Benzoylthiamine O-monophosphate	Others	Neurological Disease
Benfotiamine (S-Benzoylthiamine O-monophosphate) is an analog of vitamin B1 with higher absorption and bioavailability than vitamin B1, and is commonly used as a food supplement for diabetic complications. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage .

HY-151947

ALR2-IN-3	Aldose Reductase	Metabolic Disease
ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC₅₀s of 22 nM and 116 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications .

HY-151946

ALR2-IN-2	Aldose Reductase	Metabolic Disease
ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC₅₀s of 27 nM and 228 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications .

HY-146225

α-Amylase/α-Glucosidase-IN-2	Glucosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-2 (compound 5) is a potent α-amylase and α-glucosidase dual inhibitor with IC₅₀ values of 13.02, 13.09 µM for α-amylase and α-glucosidase, respectively. α-Amylase/α-Glucosidase-IN-2 has the potential for the research of diabetic complications .

HY-N8126

Emodin 6-O-β-D-glucoside Glucoemodin	Others	Metabolic Disease Inflammation/Immunology
Emodin-6-O-β-D-glucoside (Glucoemodin) is an active compound from Reynoutria japonica. Emodin-6-O-β-D-glucoside shows potent anti-inflammatory and barrier protective effects. Emodin-6-O-β-D-glucoside can be used for the research of diabetic complications and atherosclerosis .

HY-122963

Danshenol B	Adenosine Receptor	Metabolic Disease
Danshenol B is a diterpenoid. Danshenol B has strong aldose reductase (AR) inhibitory activity with IC₅₀ value of 0.042μM. Danshenol B can be used for the research of diabetic related complication resulted by metabolic abnormality, such as cataracts, retinopathy, neuropathy, and nephropathy .

HY-16433

Risarestat CT 112	Aldose Reductase	Metabolic Disease Inflammation/Immunology
Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications.

HY-B1202

Alrestatin 1 Publications Verification AY-22284	Aldose Reductase	Endocrinology
Alrestatin is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.

HY-B1202A

Alrestatin sodium AY-22284A	Aldose Reductase	Endocrinology
Alrestatin sodium is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.

HY-19687

Zopolrestat CP73850
Zopolrestat (CP73850) is a potent, orally active aldose reductase (AR) inhibitor with an IC₅₀ of 3.1 nM. Zopolrestat is used for the research of diabetic complications .

HY-50289

Sorbinil 1 Publications Verification	Aldose Reductase	Metabolic Disease
Sorbinil is an aldose reductase inhibitor (ARI) that prevents the accumulation of sorbitol in cells or animals. Sorbinil is useful in studying diabetes and diabetic complications, reducing AR activity and inhibiting the polyol pathway.

HY-N1362

Salvianolic acid B Maximum Cited Publications 9 Publications Verification Lithospermic acid B	Autophagy	Cardiovascular Disease
Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.

HY-13633

Exisulind 1 Publications Verification	Aldose Reductase	Metabolic Disease
Exisulind is an inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac . Exisulind inhibits aldose reductase with an IC₅₀ of 367 nM in vitro and may contribute to the beneficial pharmacological effects of sulindac on type 2 diabetic complications .

HY-115940

Aldose reductase-IN-2	Aldose Reductase	Metabolic Disease
Aldose reductase-IN-2 (Compound 5f) is a potent inhibitor of aldose reductase (AR). Aldose reductase-IN-2 has antioxidation capacity. Aldose reductase-IN-2 is a promising anti-diabetic complications agent .

HY-P2813

Hirudin	Thrombin Apoptosis	Cardiovascular Disease Cancer
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .

HY-147875

Aldose reductase-IN-6	Aldose Reductase	Metabolic Disease
Aldose reductase-IN-6 (Compound 3) is a competitive aldose reductase (AR) inhibitor with an IC₅₀ of 3.164 μM and a K_i of 0.018 μM. Aldose reductase-IN-6 exhibits no cytotoxicity against healthy cells .

HY-N2494

Hydroxyevodiamine

Rhetsinine
Aldose Reductase Inflammation/Immunology

Hydroxyevodiamine (Rhetsinine) inhibits aldose reductase with an IC₅₀ value of 24.1 μM .

Hydroxyevodiamine Rhetsinine	Aldose Reductase	Inflammation/Immunology
Hydroxyevodiamine (Rhetsinine) inhibits aldose reductase with an IC₅₀ value of 24.1 μM .

HY-10930

UNC0321 2 Publications Verification	Histone Methyltransferase GCGR Apoptosis	Cancer
UNC0321 is a potent and selective histone methyltransferase G9a inhibitor with a K_i of 63 pM and with assay-dependent IC₅₀ values of 6-9 nM. UNC0321 also inhibits GLP with assay-dependent IC₅₀ values of 15-23 nM. UNC0321 has anti-apoptotic activity and has potential application in diabetic vascular complications .

HY-N6883

6-Methoxytricin	Aldose Reductase	Metabolic Disease
6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC₅₀ values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent .

HY-14892

Gemigliptin LC15-0444	Dipeptidyl Peptidase	Metabolic Disease
Gemigliptin (LC15-0444 ) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC₅₀ of 10.3 nM for human recombinant DPP-4. Gemigliptin exhibits potent anti-glycation properties. Gemigliptin can be used for the research of advanced glycation end products (AGE)-related diabetic complications .

HY-14892A

Gemigliptin tartrate LC15-0444 tartrate	Dipeptidyl Peptidase	Metabolic Disease
Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC₅₀ of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications .

HY-106198

Lidorestat IDD-676	Aldose Reductase	Metabolic Disease
Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC₅₀ of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation .

HY-147329

RAGE 229	Others	Metabolic Disease
RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1) .

HY-N0755

Rhoifolin	Insulin Receptor GLUT NF-κB p38 MAPK Autophagy	Metabolic Disease Endocrinology Cancer
Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines .

Anti-diabetic Compound Library	740 compounds
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 740 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Hirudin	Thrombin Apoptosis	Cardiovascular Disease Cancer
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .

Emodin 6-O-β-D-glucoside Glucoemodin	Quinones Classification of Application Fields Anthraquinones Polygonaceae Source classification Reynoutria japonica Houtt. Phenols Polyphenols Plants Disease Research Fields Inflammation/Immunology	Others
Emodin-6-O-β-D-glucoside (Glucoemodin) is an active compound from Reynoutria japonica. Emodin-6-O-β-D-glucoside shows potent anti-inflammatory and barrier protective effects. Emodin-6-O-β-D-glucoside can be used for the research of diabetic complications and atherosclerosis .

Salvianolic acid B 5+ Cited Publications Lithospermic acid B	Cardiovascular Disease Structural Classification Classification of Application Fields Labiatae Source classification Samanea saman (Jacq.) Merr. Phenols Polyphenols Plants Disease Research Fields	Autophagy
Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.

Danshenol B	Structural Classification Terpenoids Labiatae Source classification Artemisia austriaca Jacq. Diterpenoids Plants	Adenosine Receptor
Danshenol B is a diterpenoid. Danshenol B has strong aldose reductase (AR) inhibitory activity with IC₅₀ value of 0.042μM. Danshenol B can be used for the research of diabetic related complication resulted by metabolic abnormality, such as cataracts, retinopathy, neuropathy, and nephropathy .

Hydroxyevodiamine Rhetsinine	Alkaloids other families Classification of Application Fields Source classification Plants Disease Research Fields Inflammation/Immunology Indole Alkaloids	Aldose Reductase
Hydroxyevodiamine (Rhetsinine) inhibits aldose reductase with an IC₅₀ value of 24.1 μM .

6-Methoxytricin	Flavonoids other families Classification of Application Fields Flavones Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	Aldose Reductase
6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC₅₀ values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent .

Rhoifolin	Structural Classification Rhus succedanea Flavonoids Classification of Application Fields Flavones Plants Disease Research Fields Endocrinology Cancer Anacardiaceae	Insulin Receptor GLUT NF-κB p38 MAPK Autophagy
Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

diabetic complications

Inhibitors & Agonists

Screening Libraries

Peptides

NaturalProducts

Natural
Products